Author: OurCrowd

Newsletter: $24M for SaNOtize anti-Covid spray

Top investment opportunitiesHong Kong’s wealthiest man invests in SaNOtizeGenesis Venture Debt II Fund targets $150M raiseMultinationals line up for OurCrowd SummitHub Security files draft prospectus for $1.28B SPAC mergerLiquid Instruments: Slashing the cost of lab testingCyfirma: 80K security cameras vulnerable to cyber attackThaicom taps Orbital Insight’s geospatial data in new collaborationIsrael’s first digital bank One Zero launches with 12K customersZippin tech to power checkout-free stores in QatarMultiverse Computing and IQM to develop quantum application processorsIntroductionsMore than 4,300 high-tech jobs Hong Kong’s wealthiest man invests in SaNOtize Li Ka-shing, the wealthiest man in Hong Kong, has invested in our portfolio company SaNOtize through his private investment arm Horizons Ventures, the South China Morning Post reports. Horizons joins OurCrowd in leading SaNOtize’s $24M Series B round, which will help fund the third phase of clinical trials for its nasal spray that treats and prevents Covid-19. “We look forward to expanding our clinical research and working towards regulatory approval in the United States and Canada,” says Gilly Regev, SaNOtize Co-founder and CEO. Agricultural Bank of China International is also participating in the financing round, which...

Read More